Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 60

1.

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.

Campbell N, Ayub A, Boustani MA, Fox C, Farlow M, Maidment I, Howards R.

Clin Interv Aging. 2008;3(4):719-28.

2.
3.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
4.
5.

Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease.

Haywood WM, Mukaetova-Ladinska EB.

Am J Geriatr Pharmacother. 2006 Sep;4(3):273-86. Review.

PMID:
17062329
6.

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C.

Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. Review.

PMID:
16323253
7.
8.

The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.

Thompson S, Lanctôt KL, Herrmann N.

Expert Opin Drug Saf. 2004 Sep;3(5):425-40. Review.

PMID:
15335298
9.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. Review.

PMID:
12391943
10.
11.
12.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
13.

Pharmacologic treatments of dementia.

Bonner LT, Peskind ER.

Med Clin North Am. 2002 May;86(3):657-74. Review.

PMID:
12171061
14.

The use of cognitive enhancers in behavioral disturbances of Alzheimer's disease.

Miller LJ.

Consult Pharm. 2007 Sep;22(9):754-62. Review.

PMID:
18198970
16.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
17.

Behavioral effects of current Alzheimer's disease treatments: a descriptive review.

Cummings JL, Mackell J, Kaufer D.

Alzheimers Dement. 2008 Jan;4(1):49-60. doi: 10.1016/j.jalz.2007.10.011. Review.

PMID:
18631950
18.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
19.

Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.

Lockhart IA, Mitchell SA, Kelly S.

Dement Geriatr Cogn Disord. 2009;28(5):389-403. doi: 10.1159/000255578. Epub 2009 Nov 6. Review.

20.

The ABC of Alzheimer's disease: behavioral symptoms and their treatment.

Grossberg GT.

Int Psychogeriatr. 2002;14 Suppl 1:27-49. Review.

PMID:
12636179

Supplemental Content

Support Center